Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)
McGill University Health Centre/Research Institute of the McGill University Health Centre
McGill University Health Centre/Research Institute of the McGill University Health Centre
BioNTech SE
Emory University
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
BeOne Medicines
Bristol-Myers Squibb
Swiss Cancer Institute
Institut Claudius Regaud
AntiCancer Research Jamaica
Ohio State University Comprehensive Cancer Center
Danish Gynecological Cancer Group
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
AstraZeneca
ALX Oncology Inc.
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
University of Pittsburgh
University of Chicago
Mayo Clinic
Damanhour University
Alliance for Clinical Trials in Oncology
Asan Medical Center
MedSIR
Actuate Therapeutics Inc.
Asan Medical Center
Gustave Roussy, Cancer Campus, Grand Paris
H. Lee Moffitt Cancer Center and Research Institute
CanariaBio Inc.
Merck Sharp & Dohme LLC
Arcus Biosciences, Inc.
National Institutes of Health Clinical Center (CC)
University of Iowa
Bristol-Myers Squibb
Wake Forest University Health Sciences
Ohio State University Comprehensive Cancer Center
AstraZeneca
University of Nebraska
Eastern Cooperative Oncology Group
Hoosier Cancer Research Network
Beijing Konruns Pharmaceutical Co., Ltd.